Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Summary
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Buy: Beigene

09/14/2021 | 08:05am EST


ę MT Newswires 2021
All news about BEIGENE, LTD.
12:04pNomura Adjusts BeiGene to Neutral From Not Rated, Sets $355.83 Price Target
MT
12/06BEIGENE : Announces Pricing of its RMB22.2 billion (US$3.5 billion) Initial Public Offerin..
PU
12/06BEIGENE, LTD. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
12/06BEIGENE, LTD. : Entry into a Material Definitive Agreement, Other Events, Financial Statem..
AQ
12/06Asian ADRs Move Higher in Monday Trading
MT
12/06Factbox-U.S.-listed Chinese firms with secondary listings at home and Hong Kong
RE
12/03China's Medical Products Regulator Approves BeiGene's Sylvant for Multicentric Castlema..
MT
12/03Beigene Grants Share Options to Five Employees
MT
12/03China Includes Three Beigene Drugs to New National Reimbursement Drug List
MT
12/02BeiGene and EUSA Pharma Announce NMPA Approval of SYLVANT« (Siltuximab for Injection) i..
BU
More news
Analyst Recommendations on BEIGENE, LTD.
More recommendations
Financials (USD)
Sales 2021 1 182 M - -
Net income 2021 -1 234 M - -
Net cash 2021 3 487 M - -
P/E ratio 2021 -27,1x
Yield 2021 -
Capitalization 32 604 M 32 604 M -
EV / Sales 2021 24,6x
EV / Sales 2022 21,7x
Nbr of Employees 7 600
Free-Float 67,7%
Chart BEIGENE, LTD.
Duration : Period :
BeiGene, Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIGENE, LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 317,25 $
Average target price 429,59 $
Spread / Average Target 35,4%
EPS Revisions
Managers and Directors
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President & Chief Operating Officer
Julia Wang Chief Financial & Accounting Officer
Jane E. Huang Chief Medical Officer-Hematology
Lai Wang Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
BEIGENE, LTD.15.80%30 750
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137